Chronic myeloid leukaemia is typically characterised by the presence of dysregulated BCR–ABL tyrosine kinase activity, which is central to the oncogenic feature of being resistant to a wide range of cytotoxic agents. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.